Goal directed preemptive ephedrine attenuates the reperfusion syndrome during adult living donor liver transplantation  by Fayed, Nirmeen A. & Murad, Wessam S.
Egyptian Journal of Anaesthesia (2014) 30, 187–195Egyptian Society of Anesthesiologists
Egyptian Journal of Anaesthesia
www.elsevier.com/locate/egja
www.sciencedirect.comResearch ArticleGoal directed preemptive ephedrine attenuates
the reperfusion syndrome during adult living donor
liver transplantation* Corresponding author. Tel.: +20 1113320976.
E-mail address: drnirmeena@yahoo.com (N.A. Fayed).
Peer review under responsibility of Egyptian Society of Anesthesiol-
ogists.
Production and hosting by Elsevier
1110-1849 ª 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists.
Open access under CC BY-NC-ND license. http://dx.doi.org/10.1016/j.egja.2013.10.002Nirmeen A. Fayed a,*, Wessam S. Murad ba Department of Anesthesia, National Liver Institute, Menoufeya University, Egypt
b Public Health and Community, National Liver Institute, Menoufeya University, EgyptReceived 27 July 2013; revised 2 October 2013; accepted 20 October 2013





Liver transplantationAbstract Background: End-stage liver disease is associated with marked hemodynamic distur-
bances that are further deteriorated during liver transplantation and is aggressively represented
in the form of postreperfusion syndrome (PRS).
Aim: The aim was to test the hypothesis that preemptive ephedrine administration pre-reperfusion
targeting a rational level of mean arterial blood pressure (MAP) of 85–100 mmHg, may reduce the
incidence of PRS.
Patient and methods: One hundred recipients for adult living donor liver transplantation (ALDLT)
were prospectively randomized into 2 groups; group C, control group and group E, who received
ephedrine 2.5–5 mg/min starting 5 min before reperfusion till mean arterial blood pressure
(MAP) reached 85–100 mmHg. Hemodynamic parameters including MAP, heart rate (HR), Trans-
esophageal Doppler (TED) parameters including corrected ﬂow time (FTc), systemic vascular resis-
tance (SVR), and cardiac output (COP) were measured; just predrug administration, just before
reperfusion, just after reperfusion, 5 min after reperfusion and at the end of surgery. Cold and warm
ischemia times (C/WIT), duration of anhepatic phase and total duration of surgery were recorded.
The incidence of PRS, the need of rescue vasoconstrictor for hemodynamic instability at time of
reperfusion, need for postreperfusion vasoconstrictor infusions, over shooting of hemodynamics,
postreperfusion ﬁbrinolysis indicated by ﬁbrinogen level and maximum lysis parameter of rota-
tional thromboelastometry (ROTEM) were compared between both groups.
Results: The mean dose of ephedrine required was (12.5 ± 7.5 mg). Group E had statistically
signiﬁcant increase in MAP, SVR, and COP; just before reperfusion, just after reperfusion and
188 N.A. Fayed, W.S. Murad5 min after reperfusion readings. There were no statistical signiﬁcant differences between the 2
groups at the end of surgery. The incidence of PRS and the need of rescue adrenaline at the time
of reperfusion, and the postreperfusion need for vasoconstrictor infusion decreased signiﬁcantly
in group E when compared to group C. Also postoperative mechanical ventilation decreased signif-
icantly in group E.
Conclusion: The preemptive goal directed titration of ephedrine against a target MAP pre-reperfu-
sion could decrease the incidence of PRS by 40%, attenuated the hypotensive response to reperfu-
sion and decreased the need for postreperfusion vasoconstrictor support without over shooting of
any of the monitored hemodynamic indices.
ª 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Anesthesiologists.
Open access under CC BY-NC-ND license.1. Introduction
End-stage liver disease is characterized by hyperdynamic,
hyporeactive circulation with reduced effective circulating
volume, presented with increased COP, low SVR, and low
arterial blood pressure [1]. Liver transplantation surgery
adds further hemodynamic burden with signiﬁcant instabil-
ity which is aggressively presented in the form of PRS [2].
PRS occurs at graft reperfusion namely after unclamping
of the portal vein and characterized by a marked decrease
in systemic blood pressure, SVR, and a moderate increase
in pulmonary arterial pressure [3]. The underlying mecha-
nisms of these severe hemodynamic changes are complex.
The immediate severe hemodynamic effects of PRS may
be the result of the heart and vasculature being transfused
from the new graft with a large bolus of acidotic, hyperka-
lemic, cold ﬂuid containing other vasoactive agents that
have an immediate deleterious effect on cardiac function
and vascular tone [4].
Proinﬂammatory cytokines such as interleukin 6 or tumor
necrosis factor alpha are produced during ischemia and are
also possibly involved in the production of hypotension at that
time [5,6]. Moreover, ischemia/reperfusion syndrome, occur-
ring in every liver transplant procedure, could be correlated
with the hemodynamic changes. PRS was considered when
the mean arterial blood pressure was 30% lower than the
previous value immediately at the end of the anhepatic stage
and lasted for at least 1 min within the 5 min after unclamping
[3,5,7], development of asystole, signiﬁcant arrhythmias, or
signiﬁcant ﬁbrinolysis requiring pharmacological intervention
[8]. The reported incidence of PRS varies greatly (12–81%)
with the study design [9–12].
PRS is important in that it is associated with increase in
blood transfusion, a higher incidence of postoperative allograft
loss, higher recipient mortality and worse outcomes [8,13,14].
Many trials have been attempted to attenuate the effect of
RPS through either targeting the implicated mediators
[9,15,16] or preventing the hypotensive response to the reperfu-
sion event using vasoconstrictors [17–19].
This study tested the hypothesis that preemptive ephedrine
administration pre-reperfusion targeting a rational level of
MAP (85–100 mmHg) can reduce the incidence of PRS with-
out over shooting of hemodynamics.2. Patients and methods
After approval of the local ethical committee and written in-
formed consent, recipients of ALDLT, in the period betweenMay 2010 and January 2013 were prospectively considered
for the study. Patients with cardiac dysfunction, including dys-
rhythmia, pulmonary hypertension, coronary artery disease,
and valvular heart disease, patients on preoperative beta
blockers, intraoperative hemodynamically unstable patients re-
quired additional intravascular volume and vasoactive drug
infusion or had uncorrectable electrolytes and an acid–base
imbalance for at least 10 min before reperfusion were excluded.
Patients were randomly allocated via a computer-generated
random number table to control group (group C) and ephed-
rine (group E) who received ephedrine 2.5–5 mg every minute
(according to the response) starting 5 min before reperfusion
till MAP reaches 85–100 mmHg. The volume of the injectate
was adjusted to 10 mL containing 25 mg ephedrine and given
1–2 ml/min. via the external jugular line. An event marker
was added to the anesthesia monitoring system, and the timer
was started at reperfusion. The onset of hypotension was noted
when MAP fell more than 30% within 5 min after reperfusion
vs. the baseline level at the time of reperfusion and continued
therefore more than 1 min. If the patients developed PRS, res-
cue incremental boluses of epinephrine (10 lg) each were given
to restore hemodynamic stability. Patients who developed PRS
received noradrenalin infusion when MAP continued to be
< 60 mmHg after reperfusion despite adequate volume
resuscitation.
Anesthetic management was the same in both groups. An
intermittent rescue intravenous ephedrine 2.5 mg every min-
ute was given for intraoperative hypotension (deﬁned as a
20% decrease from baseline mean arterial pressure). An
arterial pH less than 7.2 that was accompanied by a base
deﬁcit greater than 10 mmol/L was treated with sodium
bicarbonate. An ionized calcium level less than 1.0 mmol/L
was treated with calcium chloride, and hyperkalemia
(>6 mmol/L) after acidosis correction was treated with
glucose/insulin infusion. TED probe (cardio QTM; Deltex
Medical, Chichester, UK) was inserted orally and then the
probe was rotated on its axis to achieve an optimal signal
for hemodynamic monitoring and ﬂuid optimization. All pa-
tients received Ringer’s acetate: 6 mL kg1 h1 as a continu-
ous infusion. TED protocol adopted by Ivan and colleagues
[20] Fig. 1 was followed to correct hypovolemia using
HES130/0.4. Albumin 5% was given for more colloid
requirements and to compensate for half the volume of asci-
tes if present.
Blood product transfusion was managed according to RO-
TEM based protocol [21] Fig. 2. FFPs were given in a dose of
10 ml kg1, cryoprecipitate in a dose of 1 unit 10 kg1, and
platelets in a dose of 6–12 units to be repeated when indicated.
HCT was kept always above 25% by giving PRBCs. Tranex-
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Figure 1 ROTEM guided hemostatic protocol. Extem; extrinsically activated thromboelastometry tests. FIBTEM; measures the
ﬁbrinogen activity. CT; clotting time, MCF; maximum clot formation. ML (the maximum lysis); represents the maximum ﬁbrinolysis
detected during the analysis, deﬁned as the ratio of the lowest amplitude after reaching of the MCF and the MCF.
Preemptive ephedrine for reperfusion syndrome 189amic acid was given if there is evidence of hyperﬁbrinolysis as
indicated by ROTEM in a dose of 20 mg kg1.
Intraoperative blood loss: (BL) was calculated from a
modiﬁcation of the Gross formula [22], in addition to the
quantity of transfused red blood cells transfused to keep
HCT 25%.
Same surgical techniques were used for all cases using the
piggyback technique. The position of the venous clamp was
adjusted to achieve an adequate cardiac preload with a stable
arterial pressure. Neither venovenous bypass nor temporary
portocaval shunting was used. After the completion of the
portal vein anastomosis, the liver graft was reperfused via
the consecutive release of the clamps over the hepatic and por-
tal veins. The end-to-end anastomosis of the hepatic artery and
the duct-to-duct anastomosis of the bile duct were performed
sequentially. All patients were transported to the ICU at the
end of the operation where they were extubated.
Measurements: hemodynamics; MAP, HR, TED param-
eters including (FTc, SVR, COP) are measured just pre-
drug administration, just before reperfusion, just after
reperfusion and 5 min after reperfusion and at the end of
surgery. The incidence of PRS, need for rescue vasocon-
strictor for hemodynamic instability at time of reperfusion,
need for postreperfusion vasoconstrictor infusions, postrep-
erfusion ﬁbrinolysis indicated by ﬁbrinogen level and max-
imum lysis parameter of ROTEM, AST, ALT, serum
bilirubin and lactate, and postoperative duration of
mechanical ventilation and ICU stay were compared be-
tween both groups.3. Statistical analysis
Prospective power analysis showed that a sample size of 50 pa-
tients per study group would have 80% power at the 5% sig-
niﬁcance level to detect a difference of 26% in the incidence
of hypotension in the study group compared with control,
assuming a baseline incidence of 46% (median of published
incidences ranging from 12% to 81%), as reported in a pub-
lished study of a similar patient group [9–12].
Data were analyzed on a personal computer using IBM
SPSS, version 20 (SPSS, Chicago, IL). Normality of quantita-
tive data distribution was tested using the 1-sample Kolmogo-
rov–Smirnov goodness-of-ﬁt test. Normally distributed
quantitative data were presented as mean (SD), and between-
group differences were compared parametrically using the
independent-samples Student’s t test. Non-normally distrib-
uted numerical data were presented as median (range), and
intergroup differences were compared non-parametrically
using the Wilcoxon rank sum test. Qualitative data were pre-
sented as ratio, and differences between the 2 groups were
compared using the personal v2 test with application of Fisher
exact test, when appropriate. All reported P values are 2 tailed.
P< 0.05 is considered statistically signiﬁcant.4. Results
One hundred and ten recipients were considered for the study;
3 cases were excluded preoperatively due to beta blocker
Figure 2 ODM guided ﬂuid management, FTc; corrected ﬂow time, SV; stroke volume.
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intraoperative vasoactive drug infusion. The remaining 100 pa-
tients completed the study. Preoperative patients’ characteris-
tics are shown in Table 1. There was no statistically
signiﬁcant difference regarding MELD score, GBWR, cold
ischemia time, duration of anhepatic phase, and total duration
of surgery. The donors were all living, with steatosis <10%, of
age (28.5 ± 4.8) and (26.9 ± 5.1) in both groups C and E
respectively. Three patients in each group received tranexamic
acid according to ROTEM readings. The mean dose of ephed-
rine required to achieve the target level of blood pressure was
(12.5 ± 7.5 mg) with minimum 5 mg and maximum 25 mg.
There was no statistically signiﬁcant difference regarding
blood loss and transfusion requirements of both ﬂuids and
blood products between the 2 groups. Table 2 shows the hemo-
dynamic changes as presented by MAP, HR and TED param-
eters where group E had statistically signiﬁcant increase in
MAP, SVR, and COP Just before reperfusion, just after reper-
fusion and 5 min after reperfusion. While there were no statis-
tical signiﬁcant differences between the 2 groups at the end of
surgery, the changes in FTc were inversely related to the SVR.The incidence of PRS and the need of rescue adrenaline at the
time of reperfusion, and the postreperfusion need for vasocon-
strictor infusion decreased signiﬁcantly in group E when com-
pared to group C. Also postoperative need for mechanical
ventilation decreased signiﬁcantly in group E, while there were
no statistical signiﬁcant differences regarding the laboratory
results as shown in Table 3. Five cases in group C and 1 case
in group E developed arrhythmia at reperfusion which was
managed uneventfully and no reported cases of cardiac arrest.
5. Discussion
Prevention and treatment for PRS are important targets dur-
ing liver transplantation. Protocols that aim to prevent hypo-
tension may result in better outcomes than those designed to
treat hypotension. Pharmacological interventions have been
tried by many investigators. In this study, preemptive ephed-
rine could decrease the incidence of PRS by 40% (60% in
group C vs. 20% in group E). Also ephedrine attenuated the
hypotensive response to reperfusion (36% drop in blood
pressure in group C vs. 26% drop in MAP in group E when
Table 1 preoperative patients’ characteristics and clinical data.
Variables Group C (n= 50) Group E (n= 50)
Age 44.95 ± 8.7 41.5 ± 10.7
Sex 42/8 44/6
Etiology; HCV/HCV+ HCC 38/12 35/15
MELD 16.1 ± 3.1 17.7 ± 3.6
GBWR 1± 0.16 1.03 ± 0.18
Cold ischemia time (Min) 34 ± 3.6 35 ± 3.1
Warm ischemia time (Min) 45.75 ± 6.8 46.55 ± 5.9
Duration of surgery (H) 12.55 ± 1.5 12.25 ± 1.61
Duration of anhepatic phase (Min) 114.5 ± 31 117.1 ± 29
Blood loss (ML) 2198.5 ± 719 2219.5 ± 779
Ringer acetate (L) 5.13 ± 0.86 4.92 + 0.69
Albumin (L) 1.2 ± 0.25 1.1 + 0.30
Voluven 130/0.4 (L) 2.05 ± 0.49 1.93 + 0.44
Packed red blood cells (units) 4.12 ± 2.4 3.9 ± 2.8
Fresh frozen plasma (units) 4.62 ± 3.1 4.8 ± 2.9
Cryoprecipitate (units) 3.2 ± 1.8 2.9 ± 1.9
Platelets (units) 1.8 ± 1.1 1.6 ± 1.2
Group C, control group; group E; ephedrine group; HCV; hepatitis C virus, HCC; hepatocellular carcinoma, MELD; model of
end-stage liver disease, GBWR; graft body weight ratio. No statistically signiﬁcant differences between both groups regarding
the listed parameters.
Preemptive ephedrine for reperfusion syndrome 191comparing the pre-reperfusion readings with the just after
reperfusion readings) and decreased the need for postreperfu-
sion vasoconstrictor support without over shooting of any of
the monitored hemodynamic indices. The postoperative course
was comparable when comparing both groups apart from the
duration of postoperative need for mechanical ventilation sup-
port which was signiﬁcantly lower in group E.
In this study, a mean dose of (12.5 ± 7.5 mg) ephedrine
was given, and Iqbal et al. [23] found that a dose of 15 mg
of prophylactic intravenous ephedrine can effectively prevent
spinal induced maternal hypotension during cesarean section
without adverse effects like reactive hypertension.
Pharmacological block of the postreperfusion hemody-
namic changes including bradycardia and hypotension has
been previously tried. Acosta et al’s. study was conducted with
atropine which abolished bradycardia even when PRS oc-
curred but failed to block the decrease in MAP [18].
In a recent study, Ryu et al. [19] have demonstrated that
commonly used vasopressors such as epinephrine and phenyl-
ephrine are helpful in preventing PRS as phenylephrine is
effective in treating acute hypotension caused by systemic
vasodilatation, which is the most suspected cause of hypoten-
sion in liver transplant recipients, especially during the reperfu-
sion period. In addition, frequent bradycardia during
reperfusion of the liver graft makes epinephrine an appropriate
rescue drug of choice.
A major concern after preempetive vasopressor administra-
tion was hemodynamic indices overshooting. As not all recip-
ients will develop PRS, a preemptive management could result
in unintended hemodynamic overshooting in some patients at
reperfusion. This what Ryu et al. [19] tried to avoid in their
study by adjusting doses on the basis of the literature [17]
and their clinical experience with PRS but they had still re-
corded some cases of hemodynamic overshooting. To solve
this problem the current study used ephedrine, which is many
times less potent than epinephrine. The protocol of titrating
the dose of ephedrine against target level of blood pressurehas effectively prevented hemodynamic overshooting, as we
did not report any case of hemodynamic overshooting, as well
as it decreased the incidence of PRS compared to that reported
by Ryu et al. [19] using epinephrine and phenylephrine (the de-
creased incidence in the current study was 40% compared to
the study of Ryu who reported 38% decrease with epinephrine
and 29% with phenylephrine). The incidence of PRS in control
patients of Ryu et al’s. [19] study was 77% vs. 60% in the cur-
rent study. This may be explained by only including living do-
nors in our study while Ryu et al. included living and deceased
donors with possible higher CIT which could affect the inci-
dence of PRS.
Ephedrine may be a good choice in preventing PRS during
liver transplantation for 2 reasons; 1st, ephedrine causes higher
blood pressure, and less increase in hart rate when used in
treatment of hypotension when compared to phenylephrine
as reported by Simin et al. [24] and this appeared more appro-
priate for the hyperdynamic state of cirrhotic patients; 2nd, the
effects of ephedrine last 7–10 times longer than epinephrine
which could help maintaining an acceptable level of blood
pressure after reperfusion and so has a sparing effect on other
vasoconstrictors requirement .
The factors that could affect the incidence of PRS were
comparable in both groups. Of these factors; CIT, It has been
found that the duration of cold ischemia is a risk factor for
PRS [25,26]. Also, the duration of anhepatic phase and total
duration of surgery were comparable in both groups. Ijtsma
et al. [27] showed that an anhepatic phase over 100 min is an
independent factor for predicting graft dysfunction as the pro-
longed duration of an anhepatic phase can aggravate acidosis
of the gut, which may subsequently inﬂuence the hemodynam-
ics after reperfusion.
In this study some surgical maneuvers might also affect the
incidence of PRS as piggyback technique which is used in all
cases. This technique demonstrated better hemodynamic bal-
ance and less frequent PRS in comparison with total clamping
of the inferior vena cava (IVC) and venovenous bypass [18].
Table 2 Hemodynamic changes in both groups throughout the study period.
Variables Measuring point
Group Pre drug P Just before reperfusion P Just after reperfusion P 5 min after reperfusion P End surgery P
MAP (Mm/Hg) C 73.35 ± 5.6 0.2 67.95 ± 7.43 0.0002 43.45 ± 5.2 0.009 54.3 ± 5.5 0.02 62 ± 6.7 0.1
E 74.1 ± 6.4 90.6 ± 5.4 69.1 ± 5.5 68.5 ± 7.5 69 ± 6.3
HR (B/Min) C 93.75 ± 9.18 0.35 100.25 ± 8.58 0.0006 119.35 ± 6.70 0.19 112.85 ± 6.47 0.30 109.85 ± 5.61 0.3
E 94.05 ± 9.5 110.6 ± 8.9 115.25 ± 12.8 113.1 ± 7.07 103.6 ± 6.57
FTc (ms) C 330.4 ± 19.12 0.59 325.1 ± 7.04 0.0004 383.8 ± 17.3 0.01 371.3 ± 9.3 0.01 368.3 ± 14.5 0.53
E 327.55 ± 14.31 316.6 ± 6.81 362.1 ± 11.01 365.7 ± 10.6 369.6 ± 12.7
SVR (Dynes s/cm5) C 714 ± 109 0.8 674.5 ± 65.25 0.0001 579.5 ± 72.1 0.01 615.5 ± 76.05 0.04 625.5 ± 74.5 0.72
E 719 ± 99. 6 788.65 ± 83.6 693.65 ± 94.40 678.65 ± 81.64 633.1 ± 62.3
COP (L/M) C 7.9 ± 0.8 0.52 8.39 ± 1.0 0.002 10.94 ± 1.0 0.001 10.2 ± 1.2 0.04 9.4 ± 1.2 0.05
E 7.8 ± 0.7 9.485 ± 0.7 9.8 ± 0.83 9 ± 1.4 8.9 ± 1.13
HCT (%) C 31.6 ± 3.08 0.76 28 ± 1.97 0.76 25.75 ± 1.63 0.47 25.8 ± 1.4 0.3 27.15 ± 1.63 0.77
E 31.9 ± 3.21 27.8 ± 2.16 26.4 ± 1.69 26.3 ± 1.5 27.4 ±.69
Group C, control group (n= 50); group E; ephedrine group (n= 50); MAP; mean arterial blood pressure, HR; heart rate, FTc; corrected ﬂow time, SVR; systemic vascular resistance, COP; cardiac



















Table 3 Patients clinical and laboratory outcome in both groups.
Variables Measuring point Group C (n= 50) Group E (n= 50)
Incidence of PRS (%) 30/50 (60%) 10/50 (20%)*
Rescue adrenalin at reperfusion
% of patients required 80% 20%*
Dose/ug median (range) 30 (5–50) 5 (0–20)*
Postreperfusion noradrenalin infusion 9/50 3/50*
Duration of postoperative MV (H) 8.23 ± 7.76 6.69 ± 8.679*
ICU stay/days 5.53 ± 2.51 5.77 ± 2.44
ML (%) Preoperative 10.9 ± 05.6 11.1 ± 04.8
½ h after reperfusion 12.8 ± 05.4 12.2 ± 04.9
Fibrinogen (mg/dl) Pre-reperfusion 121 ± 17.8 126 ± 19.3
End surgery 62.9 ± 8.9 65.1 ± 9.2
Bilirubin (mg/dl) Preoperative 3.79 ± 1.62 3.66 ± 1.48
POD2 6.23 ± 4.35 6 ± 4.75
Lactate Preoperative 10.8 ± 4.1 11.6 ± 2.9
POD2 17.07 ± 6.4 18.38 ± 7.7
AST (IU/L) Preoperative 59.4 ± 29.7 55.24 ± 24.1
POD2 282.5 ± 177 274 ± 185
ALT (IU/L) Preoperative 47.60 ± 21.08 45.8 ± 22.8
POD2 336.05 ± 215 323 ± 229
Group C, control group; group E; ephedrine group; MV, mechanical ventilation; POD, postoperative day.
* Denotes statistically signiﬁcant difference (P< 0.05).
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rather than preﬂushing with lactated Ringer’s solution was
followed in all cases and this might partially contribute to car-
diovascular instability [28], as preﬂushing of the graft is known
to provide hemodynamic stability in comparison with IVC
venting without ﬂushing [29,30]. Another potential contributor
to the high incidence of PRS was the use of a histidine trypto-
phan ketoglutarate solution for organ preservation [31].
In this study, systemic vascular resistance (SVR) was signif-
icantly higher in group E than in group C just before reperfu-
sion, just after reperfusion, and 5 min after reperfusion. It has
been reported that, after ephedrine administration, there was a
sequence of a transient increase in after load, followed by a
transient decrease (possibly b2-mediated) and then a sustained
increase in SVR (probably mediated by noradrenalin release)
[32]. Also cardiac output was signiﬁcantly higher in group E
compared to group C just before reperfusion. Ephedrine has
a predominant ß-effect that causes increase in arterial blood
pressure by increasing cardiac output [33]. After reperfusion,
COP was signiﬁcantly higher in group C compared to group
E which may be due to extra use of epinephrine in the control
group represented by a higher number of patients received epi-
nephrine (80% in group C vs. 20% in group E) and higher
dose required in group C compared to group E (30 lg vs.
5 lg respectively).
The FTc readings were comparable at the predrug measure-
ment and were at the lower normal range (330–360 ms) this
could be due to the use of the piggy back technique at time
of revascularization with partial IVC clamping and it was sig-
niﬁcantly lower in group E when compared to that in the
group C just before reperfusion and this was inversely related
to the changes in SVR induced by ephedrine. The 5 min after
reperfusion results also showed that FTc was still signiﬁcantly
lower in group E compared to group C this might be explainedby the more decrease in SVR in group C as a response to reper-
fusion compared to group E in which preempetive ephedrine
prevented this excessive drop. As it is known, FTc is inversely
correlated with the SVR and a longer FTc may be associated
with a low SVR, a condition that is typically occur at the time
of reperfusion of the newly implanted graft.
At the end of surgery there was no statistical signiﬁcant dif-
ference between the hemodynamic changes in both groups.
This could be achieved in control group by an extra use of
postreperfusion vasoconstrictor infusion to help maintain
acceptable hemodynamic parameters (9 patients out of 50 in
group C vs. 3 out of 50 in group E required postreperfusion
vasoconstrictor infusion).
Despite a trend toward better postoperative laboratory re-
sults in the group E there were no signiﬁcant differences be-
tween the 2 groups and this may be due to the multi factors
affecting these results beside reperfusion.
Some investigators [8,34] considered excessive ﬁbrinolysis
as a part of PRS. The current study did not reveal any statis-
tically signiﬁcant difference when comparing parameters
reﬂecting ﬁbrinolysis including maximum lysis (ML) and ser-
um ﬁbrinogen level also the number of patients required anti
ﬁbrinolytic drug was comparable in the 2 groups.
In this study, the duration of postoperative mechanical ven-
tilation was signiﬁcantly shorter in group E compared to group
C while there was no statistically signiﬁcant difference regard-
ing the duration of ICU stay. Hilmi et al. [8] found that the
ICU length of stay and days on a ventilator are greater in pa-
tients with PRS. The limitations of this study are that, the
study was not blind as the protocol of titration of the drug
against MAP did not allow this. Also, the study did not follow
up the patients’ long term outcome including complications
and survival rate. In conclusion, the goal directed titration of
ephedrine against a target MAP pre-reperfusion, could de-
194 N.A. Fayed, W.S. Muradcrease the incidence of PRS by 40%, attenuated the hypoten-
sive response to reperfusion and decreased the need for
postreperfusion vasoconstrictor support without overshooting
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